|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||459.40 - 471.50|
|52 Week Range||301.00 - 504.00|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||54.16|
|Earnings Date||Jul 24, 2020|
|Forward Dividend & Yield||2.75 (0.59%)|
|Ex-Dividend Date||Apr 30, 2020|
|1y Target Est||354.21|
The current head of global pharma technical operations at Roche (OTC: RHHBY) is jumping ship to take the lead role at Lonza (OTC: LZAGY). Pierre-Alain Ruffieux will become the new chief executive officer of the contract development and manufacturing organization on Nov. 1. Ruffieux has the extensive biopharmaceutical experience that Lonza's board of directors was looking for.
Lonza Group on Friday named a veteran Roche manager to become its new chief executive, as the Swiss contract drug manufacturer seeks to end a year of turmoil at the top and accelerates work to produce a possible COVID-19 vaccine. Pierre-Alain Ruffieux, currently head of global pharma technical operations at drugmaker Roche, will join on Nov. 1, Lonza said in a statement. Before that, Ruffieux spent 12 years at Novartis, and the 50-year-old has more than 20 years of experience in the biopharmaceuticals industry.
Lonza aims to speed completion of two commercial production lines for Moderna Inc's trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker's chairman said on Tuesday. Lonza, which hopes to make smaller batches of active ingredients for the U.S. biotechnology company's experimental vaccine by July, now aims to finish a commercial production line in Portsmouth, New Hampshire, a month or so earlier than its original December 2020 target, Albert Baehny told Reuters. A second commercial line, at Lonza's site in Visp, Switzerland, had been slated for completion in January or February 2021 but now could be ready in December, he added.
Wildlife advocates are pushing drugmakers to curb the use of horseshoe crab blood by switching to a synthetic alternative for safety tests, including those needed before a COVID-19 vaccine can be used on humans. Fishermen net hundreds of thousands of the creatures off the U.S. East Coast and Asia every year, draining their prized milky-blue blood for use in medical safety tests that detect bacterial contamination in intravenous drugs or implants. The National Audubon Society, Defenders of Wildlife and other groups called for greater use of a man-made option, called recombinant Factor C (rFC), in a statement released on Monday by umbrella organization the Horseshoe Crab Recovery Coalition.
Horseshoe crabs' icy-blue blood will remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
Many countries are cautiously emerging from lockdown but life may not completely return to normal until a coronavirus vaccine is found.
All eyes were on Moderna, which sparked a big rally on Wall Street after announcing promising early trial data of a coronavirus vaccine that is the furthest along among U.S. biotechs in the race.
Shares of Lonza Group climbed 2.9% in Swiss trade after Moderna reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus. The companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020. Lonza shares have climbed 31% this year.
Pfizer did not specify which companies within its network it is in active discussions with about shifting production. "They have been hugely helpful in the past and will help us through this," McDermott said.
The number of patients that have recovered from the coronavirus that causes COVID-19 rose to more than a million on Friday, offering a rare piece of good news in the pandemic that has caused more than 230,000 deaths and tanked economies around the world.
Biotech Moderna (NASDAQ: MRNA) announced an agreement with Swiss drugmaker Lonza Group (OTC: LZAGY) to manufacture up to a billion doses per year of mRNA-1273, Moderna's vaccine candidate for the novel coronavirus. The two companies initially plan to establish manufacturing capabilities at Lonza's facilities in the U.S. and Switzerland to make the vaccine at both locations, with additional production suites to be established across Lonza's worldwide facilities under the 10-year agreement. The companies expect to produce the first batches of mRNA-1273 at Lonza's U.S. facility in July 2020.
Moderna and Lonza, the Swiss biotechnology company, aim to make up to 1 billion doses a year of a vaccine to combat the coronavirus.
Moderna Inc's (NASDAQ: MRNA) novel coronavirus vaccine program is brimming with activity, and the latest news out of the stable Friday is a 10-year strategic collaboration deal with Lonza, a Swiss contract development and manufacturing organization. The collaboration would help scale manufacturing of mRNA-1273, a vaccine candidate targeting SARS-CoV-2. The tie-up also covers additional Moderna products in the future.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Moderna, Lonza's Deal Terms The collaboration envisages setting up manufacturing suites at Lonza's facilities in the U.S. and Switzerland to manufacture mRNA-1273.Moderna expects the technology transfer to start in June, with the first batches of the vaccine likely to be manufactured at Lonza U.S. in July.Moderna said the companies will subsequently establish production suites across Lonza's worldwide facilities that could facilitate manufacturing material equivalent of up to 1 billion doses of the vaccine per year, assuming the individual dose is 50 micrograms.Funding for manufacturing at Lonza U.S. is partly covered by Moderna's contract with the BARDA, Moderna said."This long-term strategic collaboration agreement will enable Moderna to accelerate, by 10-times, our manufacturing capacity for mRNA-1273 and additional products in Moderna's large clinical portfolio," Moderna CEO Stephane Bancel said in a statement. Earlier this week, Moderna announced the filing of an IND application for a Phase 2 study, which is expected to commence in the second quarter contingent on favorable safety data from the NIAID-led Phase 1 study that is underway now. Recently, Emergent Biosolutions Inc (NYSE: EBS) signed an agreement with Johnson & Johnson (NYSE: JNJ) to provide CDMO services for the latter's lead COVID-19 vaccine candidate, with the deal valued at $135 million.Moderna shares were rising 6.22% to $48.85 in Friday's premarket session.Related Links:The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio See more from Benzinga * The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO * The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Moderna Inc. gained 2.4% in premarket trading on Friday after the company announced a 10-year manufacturing deal with Lonza Group AG for its COVID-19 vaccine as well as its other vaccine candidates. The companies plan to set up manufacturing facilities in Switzerland, where Lonza is based, and the U.S., where they plan to make the first batch of the investigational vaccine by July. "The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale," Lonza chairman Albert Baehny said in a statement. Moderna has conducted the Phase 1 trial of its COVID-19 vaccine; a Phase 2 study is expected to begin in the second quarter. There are no proven vaccines that prevent infections of the novel coronavirus. Year-to-date, Moderna's stock has soared 135.1%, while shares of Lonza have gained 19.8%. The S&P 500 is down 9.8%.
The experimental vaccine, mRNA-1273, is being tested in early-stage trial by the U.S. National Institutes of Health, with Moderna expecting to begin mid-stage trial in the second quarter. "Over time, the parties intend to establish additional production suites across Lonza's worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide", the statement added. Earlier this month, Moderna got a $483 million funding from a U.S. government agency to accelerate its COVID-19 vaccine development.
Moody's Investors Service, ("Moody's") downgraded Innovative Water Care Global Corporation's (dba Sigura) Corporate Family Rating (CFR) to Caa1 from B3 and Probability of Default Rating (PDR) to Caa1-PD from B3-PD. Moody's also downgraded the first lien senior secured term loan to Caa1 from B3 and the second lien senior secured term loan to Caa3 from Caa2.
Europe should maintain a close relationship with China and avoid involvement in the ongoing U.S.-China trade war, said Merkel in an interview with the Financial Times. Germany and Europe should definitely “ensure that trade relations are fair," but at the same time should not “dismantle all interconnected global supply chains,” said Merkel. “In my opinion, complete isolation from China cannot be the answer,” she added.
- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Oct. 16.) Achillion Pharmaceuticals, Inc. (NASDAQ: ...
Mesoblast expects to complete filing of the rolling Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) by the end of this year. On acceptance of the filing, the product candidate is eligible for FDA priority review under its existing Fast Track designation, providing for an expedited review period. The agreement provides for Lonza to expand its Singapore cGMP facilities if required to meet long-term growth and capacity needs for the product.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 7) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Celgene ...